Results for dosage: translation from Danish to Finnish

modified release oral and transdermal dosage forms:
modified release oral and transdermal dosage forms:

stability testing requirements for new dosage forms
stability testing requirements for new dosage forms

guidelines clinical investigation of new vaccines modified release oral and transdermal dosage forms:
ohje clinical investigation of new vaccines modified release oral and transdermal dosage forms:

comparison of three dosage regimens of ciprofloxacin in urinary tract infections.
comparison of three dosage regimens of ciprofloxacin in urinary tract infections.

european drug master file procedure quality of modified release dosage forms for veterinary use
quality of modified release dosage forms for veterinary use

note for guidance on modified release oral and transdermal dosage forms: section ii (quality)
note for guidance on modified release oral and transdermal dosage forms: section ii (quality)

titel på dokumentet use of near infrared spectroscopy by the pharmaceutical industry modified release oral and transdermal dosage forms revision:
asiakirjan nimi use of near infrared spectroscopy by the pharmaceutical industry modified release oral and transdermal dosage forms revision:

quality of water for pharmaceutical use quality of water for pharmaceutical use – revision quality of modified release dosage forms for veterinary use
impurities

a. oral dosage forms; b. and transdermal dosage forms; section i (quality).
a. oral dosage forms; b. and transdermal dosage forms; section i (quality).

adjustment for baseline covariates points to consider on the use of statistical methods for flexible design and analysis of confirmatory clinical trials points to consider on clinical pharmacokinetic investigation of the pharmacokinetics of peptides and proteins note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with impaired renal function points to consider on the evaluation of the pharmacokinetics of medicinal products in the paediatric population note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with hepatic impairment note for guidance on clinical investigation of medicinal products for the treatment of psoriasis points to consider on allergic rhino- conjuctivitis addendum to the note for guidance on modified release oral and transdermal dosage forms:
adjustment for baseline covariates points to consider on the use of statistical methods for flexible design and analysis of confirmatory clinical trials points to consider on clinical pharmacokinetic investigation of the pharmacokinetics of peptides and proteins note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with impaired renal function points to consider on the evaluation of the pharmacokinetics of medicinal products in the paediatric population note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with hepatic impairment note for guidance on clinical investigation of medicinal products for the treatment of psoriasis points to consider on allergic rhino- conjuctivitis addendum to the note for guidance on modified release oral and transdermal dosage forms: